Blog
RSS FeedPosted by Michael Wonder on 22 Jun 2020
European Commission, EMA and FDA agree new priorities to strengthen their collaboration on medicines
22 June 2020 - Senior officials from the European Commission, EMA and the United States FDA held their 2020 bilateral ...
Posted by Michael Wonder on 17 Jun 2020
Regulators discuss accelerated approvals, Project Orbis at DIA
16 June 2020 - Regulators from the US FDA, European Medicines Agency and Health Canada gave their perspectives on different ...
Posted by Michael Wonder on 19 May 2020
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): an unprecedented partnership for unprecedented times
18 May 2020 - It has been more than a century since the world has encountered a pandemic like coronavirus disease ...
Posted by Michael Wonder on 14 May 2020
Russia says search for a coronavirus treatment should not be a medical ‘arms race’
14 May 2020 - Russia’s sovereign wealth fund has been funding Russian development and production of the drug favipiravir, an anti-influenza ...
Posted by Michael Wonder on 18 Apr 2020
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
17 April 2020 - The National Institutes of Health (NIH) and the Foundation for the NIH are bringing together more than ...
Posted by Michael Wonder on 07 Apr 2020
Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...
Posted by Michael Wonder on 02 Apr 2020
COVID-19 has changed how the world does science, together
1 April 2020 - Never before, scientists say, have so many of the world’s researchers focused so urgently on a single ...
Posted by Michael Wonder on 26 Mar 2020
Crowdsourcing to fight COVID-19
26 March 2020 - “We are trying to fly the plane while we are building it.” ...
Posted by Michael Wonder on 26 Mar 2020
FDA continues to support transparency and collaboration in drug approval process as the clinical data summary pilot concludes
26 March 2020 - As our society becomes more global, it has become increasingly clear that the U.S. FDA needs to ...
Posted by Michael Wonder on 26 Mar 2020
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
26 March 2020 - Collaboration to address product development and scale up challenges posed by current pandemic. ...
Posted by Michael Wonder on 23 Mar 2020
FDA and EMA collaborate to facilitate SARS-CoV-2 vaccine development
23 March 2020 - Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed ...
Posted by Michael Wonder on 26 Nov 2019
Teva, drug makers in talks with U.S. to end generics probes
26 November 2019 - Deferred prosecution agreements among resolutions discussed. ...
Posted by Michael Wonder on 21 Nov 2019
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukaemia
21 November 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, ...
Posted by Michael Wonder on 13 Nov 2019
FDA’s Project Orbis may expand to Singapore and Switzerland
12 November 2019 - The US FDA may expand a pilot project that allows for simultaneous drug approval decisions from ...
Posted by Michael Wonder on 10 Nov 2019
Patient perspective is vital to FDA's work
7 November 2019 - As an oncologist, I was eager to come work at the U.S. FDA, where I knew ...